Ibrutinib and ABT199 for CLL

Jennifer Brown, MD, PhD

Video Categories: ASH 2014

Jennifer R. Brown, MD, PhD, at Dana-Farber Cancer Institute in Boston, discusses what she believes are the most important items coming out of ASH for CLL this year. She mentions excellent study results being presented about the drugs ibrutinib and ABT199.

Related Videos

July 25, 2018

How Real-World Data Are Consolidating Our Knowledge Regarding Melanoma Treatment

Dr Sanjiv Agarwala reviews real-world data presented at ASCO 2018 on immunotherapy of melanoma that serve to reassure providers regarding current treatment approaches, but do not offer any significant practice-changing results.

September 7, 2018

Healthcare Team’s Relationship to the Patient

Dr Andrey Antov expands on how the healthcare team can work together to provide the best possible care for their patient.